Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition

Authors:
  • CPChristina M. Piarowski
    Christina M. Piarowski
  • JSJennifer K. Scott
    Jennifer K. Scott
  • CWCourtney E. Wilson
    Courtney E. Wilson
  • HLHeber I. Lara
    Heber I. Lara
  • ESErnesto Salcedo
    Ernesto Salcedo
  • AHAndrew S. Han
    Andrew S. Han
  • ELElaine T. Lam
    Elaine T. Lam
  • PDPeter J. Dempsey
    Peter J. Dempsey
  • JMJakob von Moltke
    Jakob von Moltke
  • LBLinda A. Barlow
    Linda A. Barlow

Abstract
Taste dysfunction, or dysgeusia, is a common side effect of many cancer drugs. Dysgeusia is often reported by patients treated with anti-angiogenic tyrosine kinase inhibitors (TKIs), which inhibit receptor tyrosine kinases (RTKs). However, the mechanisms by which TKIs cause dysgeusia are not understood, as the role of RTKs in adult taste homeostasis is unknown. Here, we find that treating adult mice with the TKI cabozantinib shifts the fate of differentiating functional taste cell subtypes within taste buds. Through behavioral assays, we find this cell fate shift leads to blunted responses to sweet in cabozantinib-treated mice. Finally, we show that inducible knockout of the RTK KIT, which is inhibited by cabozantinib, phenocopies taste cell fate shifts induced by TKI treatment. Our results establish KIT as a regulator of taste cell homeostasis and suggest that KIT inhibition may underlie TKI-induced dysgeusia in patients. Summary: KIT signaling blockade by tyrosine kinase inhibitors alters the fate of functional taste bud cell subtypes.
All Related Versions

This publication has 102 references indexed in Scilit: